Abbott Libre Improves T2D Management
Abbott's FreeStyle Libre tech significantly improves glucose management for Type 2 diabetes patients on basal insulin, leading to more time in target range and better HbA1c [https://www.prnewswire.com/news-releases/landmark-study-shows-libre-technology-helps-people-with-type-2-diabetes-on-basal-insulin-improve-glucose-management-302711766.html] [https://www.finanzwire.com/article/abbott-nasdaq-abt-abbotts-freestyle-libre-technology-shows-promising-results-for-type-2-diabetes-management-vFn9Hfje002]. Abbott showcased these results at ATTD 2026 [https://www.gurufocus.com/news/8701870/abbott-abt-showcases-positive-outcomes-with-freestyle-libre-in-diabetes-management].
The study, which Abbott presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 2026 conference, specifically focused on individuals with Type 2 diabetes using basal insulin. The results highlighted a significant improvement in glucose management with the FreeStyle Libre system compared to self-monitoring of blood glucose. The FreeStyle Libre users experienced a 1.4-hour increase in time spent within their target glucose range each day. Additionally, their HbA1c levels, a measure of average blood sugar over three months, decreased by 0.8%. These findings build upon previous research demonstrating the benefits of FreeStyle Libre for individuals with diabetes. Abbott is marketing the FreeStyle Libre as a tool to reduce the burden of diabetes management and improve overall health outcomes.
